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Abstract
Background: Mortality after major hepatectomy remains high and is frequently related to post-hepa-
tectomy liver failure (PHLF). Other than pre-existing liver disease and a small future liver remnant, few
patient factors or early postoperative indicators identify patients at elevated risk for PHLF and mortal-
ity.
Methods: Data on demographics, comorbidities, operative procedures and postoperative laboratory
trends were reviewed for patients submitted to major hepatectomy (at least three Couinaud segments)
for malignancy during 1998–2013. These factors were compared among patients who died within
90 days, survivors who met the 50–50 criteria and all remaining survivors.
Results: A total of 1528 patients underwent major hepatectomy during the study period. Of these,
947 had metastatic colorectal cancer and underwent resection of a median of four segments. Overall,
49 patients (3.2%) died within 90 days of surgery and 48 patients (3.1%) met the 50–50 criteria for
PHLF; 30 of these patients survived 90 days. Operative blood loss was higher in patients who died
within 90 days compared with survivors (1.0 l versus 0.5 l; P < 0.001). Despite equivalent perioperative
resuscitation and urine output, non-survivors had higher creatinine and phosphate levels than survivors
on postoperative day (PoD) 1 (1.1 mg/dl versus 0.9 mg/dl and 4.6 mg/dl versus 3.7 mg/dl, respec-
tively; P < 0.001).
Conclusions: Early trends in creatinine and phosphate (between the day of surgery and PoD 1) iden-
tify patients at risk for PHLF and mortality.
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Introduction
Incidences of mortality following hepatectomy have fallen sig-
nificantly over the last two decades. A recent study cited
major morbidity and mortality rates following elective hepate-
ctomy of as low as 20.0% and 1.6%, respectively.1 Major
hepatectomy, involving the removal of three or more liver
segments, carries a higher risk for post-hepatectomy liver fail-
ure (PHLF) than lesser resections. Despite careful patient
selection and preoperative preparation, PHLF remains a
common contributor to significant morbidity and mortality
following hepatic resection.
There have been numerous attempts to identify patients at
high risk for the development of PHLF and subsequent mortal-
ity in details that extend beyond recognition of the fact that
more extensive resections in diseased livers carry greater risk.
One series evaluating preoperative factors identified the aspar-
tate aminotransferase to platelet count ratio as valuable in
identifying patients at high risk for PHLF following surgery for
hepatocellular carcinoma.2 Other investigators noted that a
dampened rise in serum C-reactive protein (CRP) levels on
This study was presented at the Annual Meeting of the AHPBA, 11–15
March 2015, Miami, Florida.
HPB 2015, 17, 1058–1065 ª 2015 International Hepato-Pancreato-Biliary Association
DOI:10.1111/hpb.12483 HPB
postoperative day (PoD) 1 were predictive of PHLF.3 More
recently, the lack of an early drop in serum phosphate levels
was found to correlate with PHLF, morbidity and mortality.4
Efforts to identify factors that predict PHLF have been ham-
pered by the lack of a standardized definition of PHLF. One of
the more widely applied definitions of PHLF refers to the
‘50–50 criteria’, which reflect impairment in the liver’s
synthetic and excretory functions [as reflected by elevations in
the international normalized ratio (INR) and serum bilirubin,
respectively]. The original description documented an associa-
tion between PHLF and a combination of a prothrombin time
of <50% of normal (INR > 1.7) and a total serum bilirubin of
>50 mmol/l (2.9 mg/dl) on PoD 5.5 The authors found that
mortality rates after hepatectomy in patients who met both cri-
teria exceeded 50% and subsequently confirmed these findings
in a prospective study.6 When applied on PoD 5, this algo-
rithm may identify patients at elevated risk beyond the optimal
time to intervene. The early identification of patients at high
risk for PHLF might trigger a careful assessment of volume sta-
tus, or an aggressive search for vascular compromise or infec-
tious complications, with the goal of preventing the worsening
of hepatic insufficiency caused by secondary complications.
In 2011, taking into account the existing literature, the
International Study Group of Liver Surgery (ISGLS) defined
PHLF as indicated by an increased INR in the setting of hyper-
bilirubinaemia on or after PoD 5.7 Although this more encom-
passing definition identifies patients with lesser degrees of
hepatic dysfunction who may be at risk for the development of
more significant liver failure, the identification of these indi-
viduals still occurs late in the postoperative course (day 5). In
the current study, postoperative trends in laboratory values
were characterized in a large population of patients undergoing
major hepatectomy. Routinely available perioperative factors
were analysed in order to identify those that might facilitate
the earlier identification of patients at risk for PHLF and
mortality.
Materials and methods
A prospectively maintained database was established in 1992
for all patients submitted to hepatic resection at the Memorial
Sloan–Kettering Cancer Center. Since 1998, this database has
included perioperative laboratory values imported from the
electronic medical record for all patients. When approval for
the study had been obtained from the institutional review
board, the database was queried for all patients submitted to
major hepatectomy for malignancy since 1998. Major hepatec-
tomy referred to the resection of a minimum of three seg-
ments, which is consistent with the criteria used in multiple
previous studies.4,8,9
Preoperative evaluation includes standard laboratory tests,
such as liver function tests, coagulation parameters, a complete
blood count and serum chemistry. Preoperative volumetric
analysis to calculate an estimated residual liver volume (RLV)
is performed selectively, most commonly in preparation for
extended hepatectomy. Hepatic resection is performed with
minimal fluid resuscitation initially to allow for a low central
venous pressure (CVP) during resection. At the surgeon’s
discretion, intermittent hepatic inflow occlusion (the Pringle
manoeuvre) is used.
Postoperatively, all patients undergoing major hepatectomy
are observed overnight in the post-anaesthesia care unit
(PACU), and laboratory values are serially checked following
surgery. Resuscitation fluids used include normal saline,
lactated Ringer’s solution and Normosol (Hospira, Inc., Lake
Forest, IL, USA), none of which contain phosphate. Typically,
patients are transferred to the surgical ward on PoD 1. Data
on complications and mortality are entered into the database
by surgical housestaff and are reviewed for accuracy at twice-
weekly morbidity and mortality conferences. Patient demo-
graphics, comorbidities, perioperative data, postoperative com-
plications, patient deaths and pathology results are entered
prospectively into the database by trained personnel. Patients
are recorded as having cardiac disease if they carry a diagnosis
of coronary artery disease, valvular disease or arrhythmia.
Diagnoses of hepatitis and hepatic steatosis are based on
pathological assessments. Operative details reflect the primary
procedure performed, but additional procedures include wedge
resections, ablations (microwave and radiofrequency), colonic
resections, and the placement of hepatic artery infusion pumps
for intrahepatic treatment of metastatic colorectal cancer. Renal
failure is defined as indicated by either a need for renal
replacement therapy or a three-fold increase in creatinine from
baseline.
The patient population was broken into three groups to per-
mit the identification of factors associated with significant
PHLF and mortality. The first group of patients included those
who died within 90 days of surgery and inevitably included
some patients with significant liver failure who met the 50–50
criteria. The second group included patients with evidence of
significant liver failure (meeting the 50–50 criteria for PHLF),
but who survived. The third group of patients survived with-
out evidence of significant PHLF (they did not meet the 50–50
criteria). Demographic information, comorbidities, operative
details and outcomes were compared in univariate analyses
using appropriate statistical tests. Trends in perioperative labo-
ratory values were observed for serum albumin, creatinine,
phosphate, alkaline phosphate, INR, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), total bilirubin, hae-
moglobin, white blood cell count, and platelet count. Univari-
ate analyses comparing laboratory values among the different
groups (both pre- and postoperatively) were performed. Multi-
variate analysis was performed using factors that achieved a
P-value of <0.10 on univariate analysis and which were clini-
cally relevant (gender was not deemed useful to include in the
multivariate analysis). After creatinine and phosphate levels
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were found to be significantly different, changes in these
laboratory parameters were dichotomized to create clinically
relevant criteria and included in the multivariate analysis.
In order to place changes in laboratory parameters in con-
text, a chart review was conducted to compare perioperative
fluid balances between patients who died within 90 days and
those with PHLF who survived. Data on crystalloid, colloid,
blood product and urine output for the 24 h following the
start of surgery were collected and compared among groups.
In patients for whom the requisite imaging data were avail-
able, Scout Liver (Pathfinder Therapeutics, Inc., Nashville, TN,
USA) was employed to determine the predicted RLV. Compar-
isons were made between patients who died within 90 days of
surgery and patients who met the 50–50 criteria (demonstrat-
ing significant PHLF) yet survived.
Results
A total of 1528 patients who underwent major hepatectomy
for malignancy during the study period, and for whom labora-
tory values were available, were identified. Demographic data
broken down by outcome are shown in Table 1.
Operative indications and outcomes for surgery are listed in
Table 2. Patients submitted to surgery for primary malignan-
cies of the liver were over-represented in the 90-day mortality
group in comparison with the overall population (55.1%
versus 29.1%). Specifically, mortality was nearly three-fold
higher among patients submitted to surgery for primary
hepatic malignancies compared with patients submitted to
surgery for metastasis (6.0% versus 2.1%; P < 0.001).
Outcomes by operative variables are listed in Table 3. The
mortality rate in patients undergoing resection of fewer than
four segments was 1.4%, whereas that in patients undergoing
resection of at least four segments was 3.7% (P = 0.034). A
total of 49 patients (3.2%) died within 90 days after surgery.
Of these, two patients who died on the day of surgery (DoS)
and two who died shortly afterwards (<PoD 5) were diagnosed
with PHLF according to the death summary. In an additional
two patients who died without overt evidence of liver failure,
laboratory values beyond day 4 to determine whether they met
Table 1 Demographic and clinical data in 1528 patients undergoing major hepatectomy
All patients 90-day mortality
group
Survivors with
PHLF
Survivors without
PHLF
P-value
Survivors vs.
90-day mortality
group
Survivors vs.
survivors with
PHLF
Patients, n (%) 1528 (100%) 49 (3.2%) 30 (2.0%) 1449 (94.8%) N/A N/A
Age, years,
median (IQR)
60.4 (51.0–70.2) 70.2 (56.5–76.2) 68.3 (59.9–74.1) 60.0 (50.9–69.6) <0.001
Male gender,
n (%)
818 (55.9%) 32 (65.3%) 20 (66.7%) 766 (52.9%) 0.087 0.135
Diabetes
mellitus, n (%)
70 (4.6%) 4 (8.2%) 1 (3.3%) 65 (4.5%) 0.223 0.767
BMI, kg/m2,
median (IQR)
26.0 (23.0–30.0) 26.0 (23.0–29.8) 26 (24.3–28.0) 27.0 (23.0–30.0) 0.759
Steatosis, n (%) 428 (28.0%) 11 (22.4%) 5 (16.7%) 412 (28.4%) 0.372 0.161
Cardiac
disease, n (%)
94 (6.2%) 2 (4.1%) 3 (10.0%) 89 (6.1%) 0.558 0.381
Hypertension,
n (%)
178 (11.6%) 5 (10.2%) 1 (3.3%) 172 (11.9%) 0.732 0.152
Active smoker,
n (%)
529 (37.9%) 21 (42.9%) 11 (36.7%) 497 (34.3%) 0.205 0.770
COPD, n (%) 53 (3.5%) 1 (2.0%) 0 52 (3.6%) 0.568 0.292
Hepatitis, n (%) 61 (3.9%) 7 (14.3%) 0 54 (3.7%) <0.001 0.283
Neoadjuvant
chemotherapy,
n (%)
550 (36.0%) 12 (24.5%) 7 (23.3%) 531 (36.6%) 0.087 0.139
Cholestasis
(preop
bilirubin >1.5),
n (%)
86 (5.6%) 8 (16.3%) 9 (30.0%) 69 (4.8%) <0.001 <0.001
P-values are based on pairwise chi-squared analyses for categorical variables and Kruskal–Wallis tests for continuous variables.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; N/A, not applicable; PHLF, post-hepatectomy liver
failure.
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criteria for PHLF were not available. Of the remaining 43
patients, 39 (90.7%) met the ISGLS criteria for PHLF. Of the
entire cohort, 581 (38.0%) had a postoperative complication.
The most common complications were infection-related
(Table S1, online). Of the 49 patients who died within 90 days
of surgery, 12 (24.5%) developed an intra-abdominal infection,
as did 76 of the 1479 (5.1%) patients who survived
(P < 0.001). Patients in the 90-day mortality group were also
much more likely to develop renal failure [six of 49 (12.2%)
patients versus nine of 1457 (0.6%) patients; P < 0.001] than
those in the group that survived.
Of the 12 laboratory parameters measured perioperatively,
10 were statistically equivalent among the groups preopera-
tively. Preoperative serum total bilirubin levels were signifi-
cantly higher among patients who died within the first 90 days
than in survivors [0.7 mg/dl, interquartile range (IQR) 0.5–
1 mg/dl versus 0.6 mg/dl, IQR 0.4–0.8 mg/dl; P = 0.018]. Pre-
operative albumin levels were significantly lower among
patients who died within 90 days in comparison with survivors
[3.9 mg/dl (IQR: 3.7–4.2 mg/dl) versus 4.2 mg/dl (IQR: 3.9–
4.4 mg/dl); P < 0.001]. The ISGLS definition of postoperative
hepatic insufficiency, specifically an abnormal bilirubin and
INR on or after PoD 5, applied to 460 of the 1528 patients
(30.1%). Of these patients with abnormal synthetic and excre-
tory function, 39 of 460 (8.5%) died within the first 90 days
postoperatively. Calculation of the ISGLS grade of PHLF was
not possible with the database fields available. An examination
of postoperative laboratory trends in all patients showed post-
operative INR and serum bilirubin values to be significantly
higher in the group who died than in patients who survived
(Fig. S1 online), coinciding with a higher incidence of PHLF
in this population. The changes in both serum phosphate and
creatinine levels over time by outcome group are shown in
Fig. 1. Whereas estimated blood loss was higher among
patients who died, as described above, fluid resuscitation [me-
dian 7.7 l (IQR: 6.1–8.4 l) versus 6.5 l (IQR: 5.6–8.3 l);
P = 0.160] and blood product use (eight of 47 patients versus
nine of 30 patients; P = 0.457) were similar. However, patients
who died had urine output equivalent to that of patients in
the group that survived [median 1.5 l (IQR: 1.1–1.9 l) versus
1.5 l (IQR: 1.1–2.0 l); P = 0.886] during the 24 h from the
time of surgical incision, which suggests that resuscitation was
appropriate.
In efforts to create a clinically useful cut-off point to stratify
patients at higher risk for PHLF and mortality, an increase in
creatinine between the DoS and PoD 1 in combination with a
failure of the serum phosphate level to drop by 20% from the
DoS to PoD 1 were found to optimize sensitivity and speci-
ficity. These criteria selected 24 of the 46 (52.2%) patients who
died within 90 days of surgery, 17 of the 30 (56.7%) patients
who met the 50–50 criteria and survived, and 342 of the 1397
(24.5%) patients who survived without significant evidence of
PHLF. (In the present study, data for all four laboratory values
with which to evaluate the criteria were available for 90.0% of
patients.) A comparison of patients who died within 90 days
and survivors without PHLF indicated that clinically rele-
vant factors to be included in a multivariate analysis were
patient age, diagnosis (primary versus metastatic malignancy),
Table 2 Indications for surgery in 1528 patients undergoing major hepatectomy
All patients
(n = 1528)
90-day
mortality
group
(n = 49)
Survivors
with PHLF
(n = 30)
Survivors
without PHLF
(n = 1449)
P-value
Survivors vs.
90-day mortality
group
Survivors vs.
survivors
with PHLF
Malignancy, n (%) 1528 (100%) 49 30 1449
Primary, n (%) 442 (28.9%) 27 (55.1%) 13 (43.3%) 402 (27.7%) <0.001 0.0637
HCC, n (%) 154 (10.1%) 13 (26.5%) 4 (13.3%) 137 (9.5%) <0.001 0.495
Cholangio, n (%) 206 (13.5%) 12 (24.5%) 9 (30.0%) 185 (12.8%) 0.016 0.005
Hilar, n (%) 104 (6.8%) 9 (18.4%) 6 (20.0%) 89 (6.1%) <0.001 0.001
Intrahepatic, n (%) 102 (6.7%) 3 (6.1%) 3 (10.0%) 96 (6.6%) 0.897 0.458
Other, n (%) 82 (5.4%) 2 (4.1%) 0 80 (5.5%) 0.663 0.186
Metastatic, n (%) 1070 (70.0%) 22 (44.9%) 17 (56.7%) 1031 (71.2%) <0.001 0.085
CRC, n (%) 947 (62.0%) 18 (36.7%) 15 (50.0%) 914 (63.1%) <0.001 0.154
Other, n (%) 123 (8.0%) 4 (8.2%) 2 (6.7%) 117 (8.1%) 0.982 0.683
Extrahepatic tumours, n (%) 16 (1.0%) 0 0 16 (1.1%) 0.461 0.564
Pairwise comparisons between survivors and both the 90-day mortality group and patients who survived with PHLF were performed using
chi-squared analysis.
CRC, C-reactive protein; HCC, hepatocellular carcinoma; PHLF, post-hepatectomy liver failure.
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estimated blood loss, preoperative albumin levels, and the
combination of changes in creatinine and phosphate previously
noted. As only 30 patients met the 50–50 criteria and survived,
multivariate analyses comparing these patients with survivors
without PHLF were limited to the following variables: diagno-
sis (primary versus metastatic); preoperative cholestasis (total
bilirubin >1.5 mg/dl), and creatinine and phosphate changes.
The results of the multivariate analysis are shown in Table 4.
Discussion
In this series of 1528 major hepatectomies, outcomes were
comparable with those in other modern series, with a 90-day
mortality rate of 3.2% and a morbidity rate of 37.8%.
Although no novel preoperative factors associated with PHLF
or mortality following major hepatectomy were identified, the
data confirmed older age, preoperative hyperbilirubinaemia
(total bilirubin >1.5 mg/dl), lower preoperative albumin levels,
and primary liver malignancies to be associated with higher
incidences of mortality and PHLF (significant for only the first
three risk factors).
Trends in biochemical tests assessing liver function following
major hepatectomy have not been well described. One of the lar-
ger reviews included 835 patients, of whom only 384 (46.0%)
underwent major hepatectomy.10 Although INR values did
return to normal in most of the present patients (1068/1528,
69.9%) by PoD 5, total serum bilirubin was above the upper
limit of normal in 1204 of 1528 patients (78.8%), which is
Table 3 Operative data in 1528 patients undergoing major hepatectomy
All patients
(n = 1528)
90-day mortality
group
(n = 49)
Survivors with
PHLF
(n = 30)
Survivors
without PHLF
(n = 1449)
P-value
Survivors
vs. 90-day
mortality group
Survivors vs.
PHLF survivors
Patients, n 1528 49 30 1449
Preop PVE, n (%) 188 (12.3%) 6 (12.2%) 4 (13.3%) 178 (12.3%) 0.995 0.853
Estimated RLV,
median (IQR)
N/A 32.0% (22.8–41.5) 31.1% (23.8–33.6) N/A 0.761a
Repeat resection,
n (%)
119 (7.7%) 2 (4.1%) 3 (10.0%) 114 (7.9%) 0.334 0.661
Segments resected,
median (IQR)
4.0 (4.0–5.0) 4.3 (4.0–5.0) 4.1 (4.0–5.0) 4.0 (4.0–5.0) 0.043
Type of surgery,
n (%)
Right lobectomy 576 (35.8%) 18 (36.7%) 16 (53.3%) 542 (37.4%) 0.901 0.078
Right trisectionectomy 441 (28.7%) 19 (38.8%) 10 (33.3%) 412 (28.4%) 0.110 0.543
Left lobectomy 273 (17.9%) 7 (14.3%) 2 (6.7%) 264 (18.2%) 0.485 0.104
Left trisectionectomy 99 (6.5%) 2 (4.1%) 2 (6.7%) 95 (6.6%) 0.474 0.998
Non-standard
resection
73 (4.8%) 1 (2.0%) 0 72 (5.0%)
Biliary reconstruction,
n (%)
78 (5.1%) 8 (16.3%) 4 (13.3%) 66 (4.6%) <0.001 0.024
Ablation, n (%) 84 (5.5%) 5 (10.2%) 4 (13.3%) 75 (5.2%) 0.121 0.048
HAI pump, n (%) 197 (12.9%) 2 (4.1%) 3 (10.0%) 192 (13.3%) 0.062 0.610
Other intra-abdominal
procedure, n (%)
390 (25.5%) 13 (26.5%) 6 (20.0%) 371 (25.6%) 0.866 0.496
Inflow occlusion, n (%) 1361 (89.1%) 47 (95.9%) 25 (83.3%) 1289 (89.0%) 0.105 0.385
Duration, min,
median (IQR)
34 (20–49) 35 (21–45) 35 (20–60) 33 (20–48) 0.603
EBL, l, median (IQR) 0.5 (0.3–0.9) 1.0 (0.6–1.4) 0.6 (0.4–1.1) 0.5 (0.3–0.9) <0.001
OR time, min,
median (IQR)
257 (202–325) 274 (204–384) 291 (200–372) 256 (202–323) 0.088
aComparison between 90-day mortality group and survivors with PHLF.
P-values are based on pairwise chi-squared analysis for categorical variables and Kruskal–Wallis tests for continuous variables.
EBL, estimated blood loss; HAI, hepatic artery infusion; IQR, interquartile range; N/A, not available; OR, operating room; PHLF, post-hepatectomy
liver failure; PVE, portal vein embolization; RLV, remnant liver volume.
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similar to trends documented by Roberts et al.11 Consequently,
460 of 1528 patients (30.1%) met the ISGLS definition for PHLF.
However, only 8.3% of these patients died within 90 days of
surgery, which suggests that the liver dysfunction was predomi-
nantly mild and reversible. By contrast, 3.1% of patients in the
study, of whom 37.5% died, met the 50–50 criteria. Thus, both
the ISGLS and 50–50 criteria identify patients with PHLF on
PoD 5, which may make effective intervention challenging.
This analysis demonstrated an early increase in creatinine
and a delay in the typical drop in phosphate early in the
Figure 1 Perioperative laboratory trends, encompassing preoperative (within 2 weeks prior to surgery) data, day of surgery
[postoperative day (PoD) 0] data, and data to 2 weeks following surgery, for (a) serum creatinine, (b) serum phosphate, (c) international
normalized ratio (INR) and (d) total bilirubin. Values for each day were compared between the groups using the Mann–Whitney U-test.
*P ≤ 0.002 for each day the significance star refers to Figure 1(b) phosphate pod 1, 2, and 3. (b) *P < 0.001 for PoD 1 and PoD 2,
P = 0.007 for the day of surgery, P = 0.034 for PoD 3, and non-significant for all other days
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postoperative period that were more pronounced in patients
who died within 90 days of surgery than in those who survived.
Although the association between an increase in creatinine and
postoperative mortality is novel, the adverse prognostic signifi-
cance of a delayed nadir of phosphate levels has been recently
described.4
Hypophosphataemia following hepatic resection is a common
phenomenon12–14 and was originally thought to be solely a con-
sequence of consumption during liver hypertrophy. Although
the active incorporation of phosphate into the liver has been
documented to peak in the first 72 h following hepatectomy,15
this does not appear to explain hypophosphataemia. A study by
Salem and Tray demonstrated a significant increase in the uri-
nary excretion of phosphate following hepatectomy, leading its
authors to postulate that an unidentified phosphaturic protein
leads to renal wasting of phosphate postoperatively.16 This
observation has been validated, with increases in urinary phos-
phate occurring in the first few hours following surgery.17
Recently, a phosphaturic protein responsible for urinary wasting
of phosphate following hepatectomy was identified in an animal
model.18 Regardless of the cause of the hypophosphataemia, the
data demonstrate that the lack of a drop in serum phosphate
levels in the early postoperative period is associated with a higher
risk for mortality following hepatectomy, as well as non-fatal
postoperative hepatic dysfunction (as evidenced by the failure of
serum phosphate levels to drop soon after surgery among
patients who met the 50–50 criteria but survived).
The increase in creatinine levels among patients who devel-
oped PHLF and who died within 90 days after surgery (many
of whom developed multi-system organ failure) stood out as
another prominent laboratory trend and has not been previ-
ously described. Within the limits of a retrospective review,
this did not appear to be a consequence of inadequate resus-
citation. Whether the rise in creatinine represents a similar
but less severe reflection of the complex interplay between
hepatic and renal function seen in hepatorenal syndrome is
unknown.
A simultaneous increase in creatinine and the failure of phos-
phate to drop 20% between the DoS and PoD 1 identified more
than 50% of patients who went on to develop significant PHLF
or die within 90 days, and was found in fewer than 25% of
patients who survived. These criteria are highly associated with
both PHLF and mortality on multivariate analysis. As a very
early indicator of patients at risk for PHLF and death following
hepatectomy, this may permit the development of interventions
to avoid further physiologic insults that might worsen hepatic
insufficiency. The determination of exactly which interventions
might avoid progression to PHLF is unclear; however, the associ-
ations between renal function, infection and PHLF suggest some
basic interventions. For example, close attention to volume sta-
tus might correct mild renal insufficiency that develops perioper-
atively. As an arterial line is placed for surgery in most patients
undergoing major hepatectomy, those patients meeting these
criteria might be better served in an environment in which
continued goal-directed resuscitation based on arterial line
parameters can take place. Furthermore, although a 0.1-mg/dl
increase in creatinine can easily be dismissed as insignificant, this
trend may be more significant in these patients, warranting strict
avoidance of any nephrotoxic medications. As infectious compli-
cations (particularly intra-abdominal abscesses) were far more
common among patients who died within 90 days, an aggressive
search for and treatment of intra-abdominal fluid collections
might avoid the development of more significant infectious
sequelae. Finally, these patients may be referred for early postop-
erative ultrasonography to rule out any abnormalities in hepatic
arterial and venous flow or biliary obstruction that might
contribute to low-grade hepatic dysfunction. Prospective studies
will be necessary to determine if such targeted interventions will
successfully reduce the incidence of PHLF in patients identified
as being at higher risk.
Table 4 Multivariate analysis of risk factors associated with mortality and post-hepatectomy liver failure (survivors without liver failure
represent the reference group)
Factor Odds ratio (95% CI) P-value
Risk factors associated with mortality
EBL (OR associated with each 100-ml increase) 1.08 (1.04–1.11) <0.001
Primary versus metastatic disease 2.66 (1.43–5.00) 0.002
Age (OR associated with 1-year increase) 1.04 (1.01–1.07) 0.005
Preop albumin (OR associated with 0.1-mg/dl decrease) 1.11 (1.05–1.18) 0.001
Creatinine increase (PoD 1 > DoS and phosphate fails to decrease by 20% from DoS to PoD 1 2.53 (1.36–4.71) 0.003
Risk factors associated with PHLF
Primary versus metastatic disease 1.19 (0.49–2.72) 0.69
Preoperative cholestasis (total bilirubin >1.5) 7.08 (2.68–17.8) <0.001
Creatinine increase (PoD 1 > DoS and phosphate fails to decrease by 20% from DoS to PoD 1 3.89 (1.85–8.37) <0.001
95% CI, 95% confidence interval; DoS, day of surgery; EBL, estimated blood loss; OR, odds ratio; PHLF, post-hepatectomy liver failure; PoD,
postoperative day.
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Supporting information
Additional Supporting Information may be found in the online version of this
article:
Table S1. Postoperative complications.
Figure S1. Perioperative laboratory trends from the day of surgery (postop-
erative day 0), through the second week following surgery for (a) interna-
tional normalized ratio (INR) and (b) total bilirubin. The differences between
survivors and patients in each of the other two groups were statistically
significant for each day (Mann–Whitney U-test, P ≤ 0.001), except for INR
on the day of surgery (P = 0.030).
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